Ximbio is the world’s largest non-profit tech transfer organisation dedicated exclusively to life science research reagents of all kinds. Research reagents, such as antibodies, mice and cell lines are the cornerstones of basic scientific research; without them, scientists could not test their hypotheses, validate their ideas or develop new concepts. Ximbio acts a marketplace for scientists to maximise commercial opportunities for these tools and share information. Ximbio aims to unify the life science community by making research tools widely available and accelerate research. Through Ximbio:
- Researchers and technology transfer offices can virtually upload their reagents to the Ximbio website. Each reagent can be linked to the originating inventor, enabling scientists and institutions to raise the profile of their research.
- Life science companies can use Ximbio to easily source new products to augment their portfolios via a straightforward commercialisation process.
- Bench scientists can make informed decisions about which reagents to use, though the Ximbio searchable database, extensive datasheets, peer reviews and supplier options.
Ximbio raises the profile of research reagents with scientists, allows inventors to deposit them and enables sharing with the life science community. Most of these products are created through funds from the public purse; be it government or charitable donations. We believe passionately in maximising the impact by-products of research and as such Ximbio broadens the range of tools available globally. We are committed to support and advance life science research.
Ximbio originates from Cancer Research UK. Ximbio is operated as a business unit of CRUK, and focuses on all areas of biology.
“We have created Ximbio to be a place where scientists and Technology Transfer Offices can share their research, and reagents companies can source new products, in a streamlined process that saves both time and resource, maximising the visibility and impact of all research reagents. By unifying the reagent community in this way, to make tools more widely and easily available, we hope to accelerate life science research.”
Bob Bondaryk, Head of Ximbio